Prot #CLDK378A2402: An Open-Label, Multi-Center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients with Non-Small Cell Lung Cancer (NSCLC) Characterized By ALK Positivity

  • Patel, Jyoti D (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date10/23/136/30/16

Funding

  • Novartis Pharmaceuticals Corporation (Prot #CLDK378A2402)